Host factors such as polymorphisms at the IL28B/IFNL4 loci and pre-treatment levels of intrahepatic ISG expression seemed less important in determining the outcomes of IFN therapy in chimeric mice than they were in CHC patients. This evidence concerns the gene IFNA1 and cryohydrocytosis.